Targeting the translation machinery in cancer
The DOI matches its Crossref record; 291 of the 291 references it cites were found in a registry or an index.
Abstract
Dysregulation of mRNA translation is a frequent feature of neoplasia. Many oncogenes and tumour suppressors affect the translation machinery, making aberrant translation a widespread characteristic of tumour cells, independent of the genetic make-up of the cancer. Therefore, therapeutic agents that target components of the protein synthesis apparatus hold promise as novel anticancer drugs that can overcome intra-tumour heterogeneity. In this Review, we discuss the role of translation in cancer, with a particular focus on the eIF4F (eukaryotic translation initiation factor 4F) complex, and provide an overview of recent efforts aiming to 'translate' these results to the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The natural product, silvestrol, and related compounds are selective and potent inhibitors of the RNA helicase and translation initiation factor eIF4A (Eukaryotic Translational Initiation Factor 4A, also known as DDX2) [20].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [20]
In the citing paper
“Our results build on studies in mouse models of other cancers, including lymphoma, leukemia, breast, prostate, and pancreatic cancer, supporting the tolerability and efficacy of eIF4A inhibitors (15, 17, 20, 21, 38).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [38]
In the citing paper
“Many direct eIF4A/eIF4F mRNA targets have been identified and often encode proteins that drive proliferation, metastasis, and survival (11, 14, 15).”
From Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer (2023) · cites this paper as [14]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Insights into the regulation of protein abundance from proteomic and transcriptomic analyses
Vogel, C., & Marcotte, E. M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3185 · Cited by 4,195
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Research works printed but not linked: 5
- Hershey, J. W. B., Sonenberg, N. & Mathews, M. in Protein Synthesis and Translational Control (eds Hershey, J. W. B. et al.) (Cold Spring Harbor Laboratory Press, 2012)
- Pianese, G. Beitrag zur histologie und aetiologie der carcinoma histologische und experimentelle. Beitr. Pathol. Anat. Allg. Pathol. 142, 1–193 (in German) (1896). First evidence that dysregulated translation has a major role in cancer by demonstrating that cancer cells have hypertrophic and irregularly shaped nucleoli.
- De Benedetti, A. et al. CHO cells transformed by the translation factor elF-4E display increased c-Myc expression, but require overexpression of Max for tumorigenicity. Mol. Cell. Diff. 2, 347–371 (1994).
- Ron, D. & Harding, H. in Translational Control in Biology and Medicine Ch. 13 (eds Matthews, M. B. et al.) (Cold Spring Harbor Laboratory Press, 2007).
- Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140–151 (2008). · DOI · Paper page
Cited by
Items 501–600 of 899
High expression of eIF4A2 is associated with a poor prognosis in esophageal squamous cell carcinoma
Lyu, S., Lu, J., Chen, W., Huang, W., Huang, H., Xi, S., & Yan, S. (2020) · Oncology Letters · doi:10.3892/ol.2020.12038 · Cited by 12
CIP2A regulates MYC translation (via its 5′UTR) in colorectal cancer
Denk, S., Schmidt, S., Schurr, Y., Schwarz, G., Schote, F., Diefenbacher, M. E., Armendariz, C., Dejure, F. R., Eilers, M., & Wiegering, A. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03772-y · Cited by 13
“Mounting evidence indicates that protein synthesis is deregulated in tumors in a way that in total, more and different mRNAs are translated compared to normal tissue [28, 35, 36].”
D’Agostino, M., Motta, S., Romagnoli, A., Orlando, P., Tiano, L., Teana, A. L., & Marino, D. D. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.609942 · Cited by 12
“Regulation can be exerted either on the whole translation process or on specific mRNAs, and it can be mediated by different cis-acting elements present on the mRNAs, as well as by trans-acting factors (Sonenberg and Hinnebusch, 2009; Bhat et al., 2015).”
BackgroundVanner, R. J., Dobson, S. M., Gan, O. I., McLeod, J. L., Schoof, E. M., Grandal, I., Wintersinger, J. A., García‐Prat, L., Hosseini, M., Xie, S. Z.-J., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0216 · Cited by 12
“OMA is currently used to treat chronic myelogenous leukemia, is being trialed in AML, and showed activity in a preclinical model of breast cancer metastasis, but was not effective in an early-phase clinical trial against lymphoid leukemias (27–30).”
BackgroundInfluentialCompounds for selective translational inhibition
Shichino, Y., & Iwasaki, S. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102158 · Cited by 12
Eukaryotic Initiation Factor 4E (eIF4E) as a Target of Anti-Psoriatic Treatment
Golob‐Schwarzl, N., Pilic, J., Benezeder, T., Bordag, N., Painsi, C., & Wolf, P. (2023) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.12.028 · Cited by 12
Heidary, D. K., Fox-Loe, A. M., Richards, C. I., & Glazer, E. C. (2017) · SLAS DISCOVERY · doi:10.1177/2472555216684333 · Cited by 12
“Many compounds that target the ribosome are essential antibiotics, and inhibition of translation is an increasingly active area in cancer research.(20) Accordingly, early identification of compounds that modulate different aspects of the protein life cycle is important in medicinal chemistry efforts.”
BackgroundMitchell, D. C., Menon, A., & Garner, A. L. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.03.012 · Cited by 12
“Transcripts that are translated via CDT include cyclins, VEGF, c-Myc, and HIF-1α among other proteins involved in oncogenesis, highlighting the potential ramifications of dysregulated CDT in cancer (Bhat et al., 2015).”
BackgroundEffective Inhibition of MYC-Amplified Group 3 Medulloblastoma Through Targeting EIF4A1
Zhao, Y., Li, T., Tian, S., Meng, W., Sui, Y., Yang, J., Wang, B., Liang, Z., Zhao, H., Han, Y., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s278844 · Cited by 13
Role of RONS and eIFs in Cancer Progression
Helmy, Y. A. S. H., Mahmoud, S. S. M., Ngowi, E. E., Gbordzor, V., Li, T., Wu, D., & Ji, X. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5522054 · Cited by 12
Frosi, Y., Lin, Y., Jiang, S., Ramlan, S. R., Hew, K., Engman, A. H., Pillai, A., Yeung, K., Cheng, Y. X., Cornvik, T. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32463-1 · Cited by 12
“The VH-S4/1C5 structures offer two possible avenues for future lead molecule development: (1) the CDR3 loop could be used as a template to drive forward a macrocyclic discovery strategy and (2) the critical residues involved in binding eIF4E could be used as a basis for small molecule design.”
BackgroundMethodZhong, X., Persaud, L., Muharam, H., Francis, A. M., Das, D. K., Aktas, B. H., & Sauane, M. (2018) · Cancers · doi:10.3390/cancers10050153 · Cited by 12
Translating the anticancer properties of eEF2K
Gassart, A. D., & Martinon, F. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1254974 · Cited by 12
“Hence, therapeutic strategies that target components of the translation machinery to decrease protein synthesis rates and rewire translation programs hold promise in a broad range of cancer types.(1) Various compounds have been shown to affect protein synthesis and are investigated as possible cancer therapeutics.”
BackgroundNanomaterials and Nanotechnology in Medicine
Visakh, P. M. (2022) · Wiley eBooks · doi:10.1002/9781119558026.ch1 · Cited by 12
Ferrario, C., Mackey, J. R., Gelmon, K. A., LeVasseur, N., Sorensen, P. H. B., Oo, H. Z., Negri, G. L., Tse, V. W. L., Miko, S. E. S., Cheng, G., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0841 · Cited by 11
Self-citationOxo-aglaiastatin-Mediated Inhibition of Translation Initiation
Maïga, R. I., Cencic, R., Chu, J., Waller, D. D., Brown, L. E., Devine, W. G., Zhang, W., Sébag, M., Porco, J. A. J., & Pelletier, J. (2019) · Scientific Reports · doi:10.1038/s41598-018-37666-5 · Cited by 11
Self-citationRibosomopathies and cancer: pharmacological implications
Temaj, G., Saha, S., Dragusha, S., Ejupi, V., Buttari, B., Profumo, E., Beqa, L., & Saso, L. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2098110 · Cited by 11
Hamm, D. C., Paatela, E., Bennett, S. R., Wong, C.-J., Campbell, A. E., Wladyka, C. L., Smith, A. A., Jagannathan, S., Hsieh, A. C., & Tapscott, S. J. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002317 · Cited by 11
Regulation of mRNA translation by estrogen receptor in breast cancer
Fard, S. S., & Holz, M. K. (2023) · Steroids · doi:10.1016/j.steroids.2023.109316 · Cited by 11
Sanjaya, A., Ratnawati, H., Adhika, O. A., & Rahmatilah, F. R. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07428-1 · Cited by 11
“Increased protein synthesis has also been researched as a therapeutic target [74], although our data show that targeting this pathway might only limit the growth of primary tumors instead of metastasis.”
Ishikawa, C., Senba, M., & Mori, N. (2018) · Oncology Letters · doi:10.3892/ol.2018.7979 · Cited by 11
“Several pre-clinical studies reported the efficacy of NVP-BEZ235 in various lymphoid malignancies (14,16-18) and its effects, either alone or in combination with other compounds, are currently being tested in the treatment of various other malignancies (12).”
BackgroundNishimura, T., Fujii, K., Nakamura, H., Naruki, S., Sakai, H., Kimura, H., Miyazawa, T., Takagi, M., Furuya, N., Marko‐Varga, G., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99695-x · Cited by 11
Discovery of an eIF4A Inhibitor with a Novel Mechanism of Action
Zerio, C. J., Cunningham, T. A., Tulino, A. S., Alimusa, E. A., Buckley, T. M., Moore, K. T., Dodson, M. B., Wilson, N. C., Ambrose, A. J., Shi, T., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01014 · Cited by 11
He, J., Chen, Z., Xue, Q., & Shi, W. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/2946989 · Cited by 11
Unraveling the importance of the malaria parasite helicases
Tuteja, R. (2017) · FEBS Journal · doi:10.1111/febs.14109 · Cited by 11
Sbirkov, Y., Kwok, C., Bhamra, A., Thompson, A., Gil, V., Zelent, A., & Petrie, K. R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071440 · Cited by 11
“Given that aberrant eEF1A1 activities have been implicated in a number of cancers [62–64] and the translation machinery represents an important area of oncology research [65], our findings suggest new possibilities for combinatorial therapeutic approaches.”
BackgroundJuang, Y.-P., Lin, Y., Chan, S.-H., Chang, C.-K., Shie, J., Hsieh, Y. S. Y., Guh, J., & Liang, P. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103835 · Cited by 11
Signaling pathways that control mRNA translation initiation in macrophages
Tabatabaei, N., Hou, S., Kim, K.-W., & Tahmasebi, S. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109700 · Cited by 11
Cao, Y., He, Y., Yang, L., & Luan, Z. (2020) · Oncology Reports · doi:10.3892/or.2020.7856 · Cited by 11
“Targeting the initiation of translation is a rapidly emerging anti-tumor strategy in cancer treatment (8).”
BackgroundDiao, S., Zou, J. Y., Wang, S., Chan, J. E., Kortlever, R. M., Poulain, N., Ghaddar, N., Kim, H., Evan, G. I., Koumenis, C., et al. (2026) · Nature Cell Biology · doi:10.1038/s41556-026-01991-z · Cited by 10
Self-citationBcl-2highmantle cell lymphoma cells are sensitized to acadesine with ABT-199
Montraveta, A., Xargay‐Torrent, S., Rosich, L., López‐Guerra, M., Roldán, J., Rodríguez, V., Lee‐Vergés, E., de Frías, M., Campàs, C., Campo, E., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4230 · Cited by 10
“This decrease on phosphorylation was less evident by eIF4E that might be due to the regulation of this protein by other signaling pathways [48].”
BackgroundJee, H.-Y., Lee, Y.-G., Lee, S., Elvira, R., Seo, H.-E., Lee, J., Han, J., & Lee, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111824 · Cited by 10
Gable, T., Wang, Y., Clark, D. J., Kumari, P., Shetty, A. C., Li, M., & Mei, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.017 · Cited by 10
WRN modulates translation by influencing nuclear mRNA export in HeLa cancer cells
Iglesias‐Pedraz, J. M., Fossatti-Jara, D. M., Valle-Riestra-Felice, V., Cruz-Visalaya, S. R., Felix, J. A. A., & Comai, L. (2020) · BMC Molecular and Cell Biology · doi:10.1186/s12860-020-00315-9 · Cited by 10
Translational Regulation in Hepatocellular Carcinogenesis
Bračič, S., Schatz, C., & Haybaeck, J. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s255582 · Cited by 10
Exploring the targeting spectrum of rocaglates among eIF4A homologs
Naineni, S. K., Cencic, R., Robert, F., Brown, L. E., Haque, M., Scott-Talib, J., Sénéchal, P., Schmeing, T. M., Porco, J. A. J., & Pelletier, J. (2023) · RNA · doi:10.1261/rna.079318.122 · Cited by 10
Self-citationWei, N., Burnett, J. C., Crocker, D. L., Huang, Y., Li, S., Wipf, P., Chu, E., & Schmitz, J. C. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115564 · Cited by 10
STAT1-mediated translational control in tumor suppression and antitumor therapies
Wang, S., & Koromilas, A. E. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1055049 · Cited by 10
“6 inhibitors of EIF4A translational activity may hold the promise for the implementation of effective anti-cancer therapies impairing the translational effects of STAT1.(10) Such an approach may be of clinical benefit if the pharmacological eIF4A inhibitors exhibit an increased specificity for the cell-autonomous and…”
BackgroundPolysome Profiling of a Human Glioblastoma Reveals Intratumoral Heterogeneity
Lupinacci, F. C. S., Kuasne, H., Roffé, M., Vassalakis, J. A., da Silva, F. F., Santos, T. G., de Andrade, V. P., Sanematsu, P., Martins, V. R., Rogatto, S. R., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092177 · Cited by 10
“In addition, mRNA translation can be selectively modulated, which results in changes in the expression of specific subsets of proteins [10].”
BackgroundProteomic analysis of the S. cerevisiae response to the anticancer ruthenium complex KP1019
Stultz, L. K., Hunsucker, A., Middleton, S. M., Grovenstein, E., O’Leary, J., Blatt, E. B., Miller, M. E., Mobley, J. A., & Hanson, P. K. (2020) · Metallomics · doi:10.1039/d0mt00008f · Cited by 10
Silva, T. A., & de Azevedo, H. F. Z. (2020) · Journal of Proteomics · doi:10.1016/j.jprot.2020.103951 · Cited by 10
5′-Cap‒Dependent Translation as a Potent Therapeutic Target for Lethal Human Squamous Cell Carcinoma
Srivastava, R. K., Khan, J., Arumugam, A., Muzaffar, S., Guroji, P., Gorbatyuk, M. S., Elmets, C. A., Slominski, A. T., Mukhtar, M. S., & Athar, M. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.08.021 · Cited by 10
“In this regard, it is equally important to uncover the roles of eIF4E, eIF4G, and eIF4A1 binding leading to the formation of Ternary Initiation Factors Complex (TIFC) (Bhat et al., 2015).”
BackgroundTopisirović, I., & Sonenberg, N. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.05.004 · Cited by 10
Self-citationRepurposing Clemastine to Target Glioblastoma Cell Stemness
Sun, M. A., Yang, R. R., Liu, H., Wang, W., Song, X., Hu, B., Reynolds, N., Roso, K., Chen, L. H., Greer, P. K., et al. (2023) · Cancers · doi:10.3390/cancers15184619 · Cited by 9
“Gene Set Enrichment Analysis (GSEA) confirmed the clemastine-induced downregulation of genes associated with OPCs (Figure S3F,G) [65], and downregulation of genes in the protein translation machinery (Figure S3H,I), which serves a critical role in cancer cell stemness/plasticity and as a promising therapeutic target […”
BackgroundZheng, G., Tang, M., Shu, C., Xin, W., Zhang, Y., Chi, B.-B., Shi, M., Guo, X., Zhang, Z., & Lian, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03191-5 · Cited by 9
Bras, M. L., Gorelick, N. L., Pautet, S., Tyler, B., Manenti, S., Skuli, N., Millevoi, S., & Cammas, A. (2022) · Cancers · doi:10.3390/cancers14051283 · Cited by 9
eIF6 as a Promising Diagnostic and Prognostic Biomarker for Poorer Survival of Cutaneous Melanoma
Zhang, F., Waheed, S., Armato, U., Wu, J., Zhang, C., & Li, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.848346 · Cited by 9
“In this respect, a set of proteins named eukaryotic Initiation Factors (eIFs) control the onset of translation in eukaryotic cells (14).”
BackgroundPost-transcriptional regulation of myeloid cell-mediated inflammatory responses
Liu, X., Han, W., & Hu, X. (2023) · Advances in immunology · doi:10.1016/bs.ai.2023.09.001 · Cited by 9
Samykannu, G., Mariyappan, N., & Natarajan, J. (2024) · In Silico Pharmacology · doi:10.1007/s40203-024-00206-3 · Cited by 9
“In human cells, the rapid development of lung, bladder, colon, prostate, breast, head, and neck cancer is attributed to the overexpression or dysregulation of eIF4E (PDB ID: 5EI3) (Romagnoli et al. 2021; Chuet al. 2016; Bhat et al. 2015; Carroll and Borden 2013).”
Tumor Antigens beyond the Human Exome
Emilius, L., Bremm, F., Binder, A. K., Schaft, N., & Dörrie, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094673 · Cited by 9
“Given the fundamental role of translation, it comes as no surprise that multiple reviews name aberrant mRNA translation as a common characteristic of many cancers [118,119].”
BackgroundMustafa, N. B., Lee, J. X. T., Nee, H. F. A., Bi, C., Chung, T., Hart, S., & Chng, W. J. (2017) · Oncotarget · doi:10.18632/oncotarget.21988 · Cited by 9
“PI-103 did not enter clinical trials due to issues of rapid metabolism in vivo and NVP-BEZ235 is currently in several phase I/II trials for renal and prostate cancer [15].”
BackgroundHuang, L.-Q., Wei, Z., Chang, X.-X., Zheng, X., Yan, J., Huang, J. C., Zhang, J., & Sheng, L. (2020) · Biotechnology Letters · doi:10.1007/s10529-020-02878-1 · Cited by 9
The transcription factor CBFB mutations indicate an improved survival in HR+/HER2- breast cancer
Guo, L., Chen, B., Zhang, G., Wang, Y., Cao, L., Ren, C., Wen, L., Lin, J., Wei, G., & Liao, N. (2020) · Gene · doi:10.1016/j.gene.2020.144970 · Cited by 9
Kwak, J., Kim, M., Kim, S., Park, G., Jo, J., Jeong, M., Kang, S., Moon, S., Bang, S., An, H., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114501 · Cited by 9
Yin, K., Tong, M. H., Suttapitugsakul, S., Xu, S., & Wu, R. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad168 · Cited by 9
Wojtczak, B. A., Bednarczyk, M., Sikorski, P. J., Wojtczak, A., Surynt, P., Kowalska, J., & Jemielity, J. (2023) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.3c00126 · Cited by 9
Kai, J., Wang, Y., Xiong, F., & Wang, S. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.06.43 · Cited by 9
RECONSTRUCCIÓN DE SITUACIONES DIDÁCTICAS DE MATEMÁTICAS EN EL AULA. UN ESTUDIO EN PREESCOLAR
Laguna, M., & Block, D. (2020) · Revista Latinoamericana de Investigación en Matemática Educativa · doi:10.12802/relime.20.2333 · Cited by 10
Role of eIF3C Overexpression in Predicting Prognosis of Intrahepatic Cholangiocarcinoma
Xu, Y., Dong, Z.-N., Zhou, Y., Zhao, Y., Zhao, Y. F., Wang, F., Huang, X., & Guo, C.-Y. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-06878-7 · Cited by 9
eIF3 Regulation of Protein Synthesis, Tumorigenesis, and Therapeutic Response
Yin, J., Dong, Z., & Zhang, J. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6518-2_9 · Cited by 9
Li, F., Wang, Q., Xiong, X., Wang, C., Liu, X., Liao, Z., Li, K., Xie, B., & Lin, Y. (2018) · Cancer Management and Research · doi:10.2147/cmar.s158547 · Cited by 9
“10–13 Besides the amplification of eIF4E, eIF4E activity is also controlled by eIF4E-binding proteins (4E-BPs) such as 4E-BP1, 4E-BP2 and 4E-BP3.”
Senatore, E., Avolio, R., Rinaldi, L., Chiuso, F., Oliva, M. A., DˈAmbrosio, C., Bianco, A. G., Dalla, E., Pagnotta, S. M., Flammia, R., et al. (2025) · EMBO Reports · doi:10.1038/s44319-025-00425-5 · Cited by 8
“This is an important mechanism adopted by cancer cells to rapidly adapt to external stimuli, contributing to the deleterious plasticity of malignant tumors (Bhat et al, 2015; Robichaud et al, 2019; Lee et al, 2021; Galardi et al, 2016; Wahba et al, 2016).”
Eukaryotic translation initiation factor 4F: functional properties and physiological role
Shuvalova, E., Sheikh, W. A., Shuvalov, A. V., Terenin, I. M., & Alkalaeva, E. Z. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1351 · Cited by 8
“Malignant cells subvert normal translational control mechanisms to support oncogenic programs, making components of the initiation machinery promising therapeutic targets (reviewed in [ 330 , 331 ]). eIF4G dysregulation contributes significantly to tumor progression.”
Navigating heme pathways: the breach of heme oxygenase and hemin in breast cancer
Consoli, V., Sorrenti, V., Gulisano, M., Spampinato, M., & Vanella, L. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05119-5 · Cited by 8
“Numerous studies have revealed that the tumor phenotype is influenced not only by overall alterations in protein synthesis but also by specific changes in translational efficiency [39].”
Exploiting Translation Machinery for Cancer Therapy: Translation Factors as Promising Targets
Sehrawat, U. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910835 · Cited by 8
“…of eIF4A to the ribosome is 3:1, making it one of the most abundant initiation factors necessary for cap-Int dependent translation initiation [15,82]. eIF4A has been shown to play a critical role in viral replication and tumor progression, suggesting broader applications of inhibiting eIF4A…”
BackgroundCárdenas, E. L., O’Rourke, R. L., Menon, A., Vega-Hernández, G., Meagher, J. L., Stuckey, J. A., & Garner, A. L. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00466 · Cited by 8
Sharp, S. Y., Martella, M., D’Agostino, S., Milton, C. I., Ward, G., Woodhead, A., Richardson, C. J., Carr, M. G., Chiarparin, E., Cons, B. D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54356-1 · Cited by 8
mTORC1 cooperates with tRNA wobble modification to sustain the protein synthesis machinery
Hermann, J., Borteçen, T., Kalis, R., Kowar, A., Pechincha, C., Vogt, V., Schneider, M., Helm, D., Krijgsveld, J., Loayza‐Puch, F., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59185-4 · Cited by 9
“Cancer cells dysregulate translation to promote their growth 45,46 .”
Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma
Safari, M., Scotto, L., Basseville, A., Litman, T., Xue, H., Petrukhin, L., Zhou, P., Remotti, H. E., Ku, A. W., Morales, D. V., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101312 · Cited by 8
“…factors involved in transcription and translation such as MYC (Wang, 2021), histone deacetylases (Liang, 2023; Bates, 2020), or the components of the eukaryotic initiation factor 4 F (eIF4F) complex, such as eIF4E or eIF4A could be of value in the treatment of PDAC (Hao, 2020; Bhat, 2015).”
Zhou, S. Y., Appleman, V. A., Rose, C. M., Jun, H. J., Yang, J., Zhou, Y., Bronson, R. T., Gygi, S. P., & Charest, A. (2018) · Life Science Alliance · doi:10.26508/lsa.201800029 · Cited by 8
“Several inhibitors targeting the mRNA translation regulation have demonstrated anticancer activities in preclinical and clinical cancer models (Bhat et al, 2015).”
Pathogenic Roles of RNA-Binding Proteins in Sarcomas
Hai, Y., Kawachi, A., He, X., & Yoshimi, A. (2022) · Cancers · doi:10.3390/cancers14153812 · Cited by 8
Zhai, S., Lin, S., Lin, Z., Xu, J., Ji, T., Chen, K., Wu, K., Liu, H., Ying, H., Fei, W., et al. (2019) · Gastric Cancer · doi:10.1007/s10120-019-01030-x · Cited by 8
Han, L., Wu, Y., Liu, F., & Zhang, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136932 · Cited by 8
Post-transcriptional control of stress responses in cancer
Harvey, R. F., & Willis, A. E. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.10.006 · Cited by 8
Transcriptional induction of 4E-BP3 prolongs translation repression
Tsukumo, Y., Sonenberg, N., & Alain, T. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1224786 · Cited by 8
“resulting in their release from eIF4E and favoring of capdependent translation.(1) While these proteins have apparent”
BackgroundSelf-citationBridging technical innovation and computational advances in studies of RNA–protein assemblies
Ducoli, L., Srinivasan, S., Amjadi, E., & Khavari, P. A. (2026) · Nature Reviews Genetics · doi:10.1038/s41576-026-00931-9 · Cited by 7
N-MYC regulates cell survival via eIF4G1 in inv(16) acute myeloid leukemia
Peramangalam, P. S., Surapally, S., Veltri, A. J., Zheng, S., Burns, R., Zhu, N., Rao, S., Müller‐Tidow, C., Bushweller, J. H., & Pulikkan, J. A. (2024) · Science Advances · doi:10.1126/sciadv.adh8493 · Cited by 7
“Cancer cells are highly dependent on increased eIF4F activity compared to normal cells ( 56 , 57 ). eIF4E is overexpressed and known to have oncogenic potential in M4 and M5 subtypes of AML ( 58 , 59 ). eIF4A is overexpressed in AML, and its inhibition can induce anti-leukemic effects in FLT3-ITD…”
BackgroundD’Andrea, G., Deroma, G., Miluzio, A., & Biffo, S. (2024) · Cancers · doi:10.3390/cancers16132392 · Cited by 7
“Ribosome biogenesis [3–5] and translation [6,7] are described in several outstanding reviews.”
BackgroundAR and YAP crosstalk: impacts on therapeutic strategies in prostate cancer
Zheng, G., Yan, Z., Zou, J., Zou, X., Chai, K., & Zhang, G. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1520808 · Cited by 7
“Kallikrein-related peptidase 4 (KLK4) is one of the target genes of AR, which can enhance mTOR activity by inhibiting REDD1 (58). mTOR is a serine/threonine kinase that is categorized into two distinct complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (59).”
The intersection between metabolism and translation through a subcellular lens
Santoro, M. M. (2025) · Trends in Cell Biology · doi:10.1016/j.tcb.2025.05.003 · Cited by 7
Yao, B.-R., Zhang, C., Ye, Z., Li, P., & Xiao, J. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117911 · Cited by 7
RNA binding of GAPDH controls transcript stability and protein translation in acute myeloid leukemia
Shamloo, S., Schloßhauer, J. L., Tiwari, S., Fischer, K. D., Almolla, O., Ghebrechristos, Y. E., Kratzenberg, L., Bejoy, A. M., Aifantis, I., Boccalatte, F. E., et al. (2025) · RNA Biology · doi:10.1080/15476286.2025.2580180 · Cited by 7
“Alteration of protein translation is crucial in cancer, empowering cancer cells to operate independently of growth factors and drive unregulated cell proliferation [91,92].”
Istomine, R., Al-Aubodah, T.-A., Alvarez, F., Smith, J. A., Wagner, C. R., & Piccirillo, C. A. (2023) · iScience · doi:10.1016/j.isci.2023.106683 · Cited by 7
Quddusi, D. M., & Bajçinca, N. (2023) · IET Systems Biology · doi:10.1049/syb2.12066 · Cited by 7
“…pathways or pathways nurturing the process of translation. mRNA translation into protein, shapes the gene expression process; therefore, tumourigenic initiation factors, and genetically altered translational machinery (defected ribosomes as mentioned above) bring in elevated risks for cancer [42].”
Capiz, A. P., Chimal‐Vega, B., Ávila‐Barrientos, L. P., Campos-Valenzuela, A., Díaz-Molina, R. J., Muñiz‐Salazar, R., Galindo‐Hernández, O., & García‐González, V. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091179 · Cited by 7
“Together, these components form a dynamic complex crucial for efficient mRNA translation, whose dysregulation is often implicated in chemoresistance phenomena registered in cancer cells [13].”
BackgroundInhibition of coronavirus HCoV-OC43 by targeting the eIF4F complex
Feng, Y., Grotegut, S., Jovanović, P., Gandin, V., Olson, S. H., Murad, R., Beall, A. E., Colayco, S., DeJesus, P., Chanda, S. K., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1029093 · Cited by 7
“Among eIF4A inhibitors that effectively suppress SARS-CoV-2 replication, while causing minimal toxicity to host cells (Bhat et al., 2015; Pelletier et al., 2015), zotatifin is undergoing clinical evaluation (NCT04632381) (Sauvat et al.”
BackgroundSurmounting Cancer Drug Resistance: New Perspective on RNA-Binding Proteins
Feng, Y., Zhu, S., Liu, T., Zhi, G., Shao, B., Liu, J., Li, B., Jiang, C., Feng, Q., Wu, P., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16081114 · Cited by 7
“Almost all major oncogenic signaling pathways that are altered in cancer, such as PI3K/AKT/mTOR, RAS/MAPK, and Wnt/b-linked proteins, result in translational dysregulation [57,119,120].”
BackgroundUnconventional translation in cancer
Pedersen, M. T., & Jensen, K. B. (2017) · Nature · doi:10.1038/nature21115 · Cited by 7
A novel function of cIAP1 as a mediator of CHIP-driven eIF4E regulation
Seo, T. W., Lee, J. S., Choi, Y. N., Jeong, D. H., Lee, S. K., & Yoo, S. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-10358-2 · Cited by 7
A Chemical Screen Identifies a Link between Lipid Metabolism and mRNA Translation
Corman, A., Kanellis, D. C., Michalska, P., Häggblad, M., Lafarga, V., Bártek, J., Puigvert, J. C., & Fernández-Capetillo, Ó. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3001263 · Cited by 7
“For example, chemical or genetic inhibition of the eIF4F complex involved in translational initiation has shown promising results in overcoming the resistance to various cancer therapies, and several compounds are in clinical trials as antineoplastic drugs [10].”
BackgroundDissecting translation elongation dynamics through ultra-long tracking of single ribosomesPreprint
Madern, M. F., Yang, S., Witteveen, O., Bauer, M., & Tanenbaum, M. E. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.08.588516 · Cited by 7
A new IRES-mediated truncated Cx32 isoform inhibits global mRNA translation to suppress glioblastoma
Cai, S., Peng, F., Tang, H., Zhou, L., Chen, Z., Wu, P., Ou, Y., Tao, L., & Wang, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114513 · Cited by 6
Li, M., Lou, L., Ren, L., Li, Z., Han, R., Jiang, J., Qi, L., & Jiang, Y. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00457 · Cited by 6
Nair, J. J., & Staden, J. V. (2025) · Phytochemistry Reviews · doi:10.1007/s11101-025-10122-9 · Cited by 6
Translational control of leukemic metabolism and disease progression
Mercier, F., Gife, V., Aloyz, R. S., & Hulea, L. (2025) · Trends in Cell Biology · doi:10.1016/j.tcb.2025.04.006 · Cited by 6
Self-citationHypoxia-mediated regulation of mRNA metabolism: from transcription to stability
Zhang, X., Zhang, P., Zhang, C., Yuan, Z., & Li, S. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02471-x · Cited by 6
“After recruitment, the 43S preinitiation complex scans the mRNA from 5' to 3' until it recognizes the AUG start codon [83–85].”
InfluentialWang, Y., Lam, W., Chen, S., Guan, F., Dutchman, G. E., Francis, S., Baker, D. C., & Cheng, Y. (2016) · Scientific Reports · doi:10.1038/srep32832 · Cited by 6
FLI1 promotes protein translation via the transcriptional regulation of MKNK1 expression
Wang, C., Song, J., Liu, W., Yao, Y., Kapranov, P., Sample, K. M., Gajendran, B., Zacksenhaus, E., Hao, X., & Ben‐David, Y. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4943 · Cited by 6
“The dysregulation of protein synthesis by oncogenes and tumor suppressor genes is a common event in cancer (1) The therapeutic targeting of the translational machinery has thus become an area of substantive interest for cancer therapy.”
BackgroundAbdelaziz, A. M., Diab, S., Islam, S., Basnet, S. K. C., Noll, B. D., Li, P., Mekonnen, L. B., Lu, J., Albrecht, H., Milne, R. W., et al. (2018) · Medicinal Chemistry · doi:10.2174/1573406415666181219111511 · Cited by 6
Bowling, H. L., Kasper, A. C., Patole, C., Venkatasubramani, J. P., Leventer, S. P., Carmody, E., Sharp, K., Berry‐Kravis, E., Kirshenbaum, K., Klann, E., et al. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00299 · Cited by 6
Metadata
- Authors
- Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I.
- Affiliations
- McGill University Health Centre (CA)
- McGill University (CA)
- Jewish General Hospital (CA)
- Corresponding author
- Sonenberg, Nahum
- Pelletier, Jerry
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-03-06
- Volume
- 14
- Issue
- 4
- Pages
- 261-278
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2040885133
- Cited by
- 799
- References
- 291
- Citations by year
- 2026: 40 · 2025: 44 · 2024: 69 · 2023: 77 · 2022: 58 · 2021: 75 · 2020: 92 · 2019: 70 · 2018: 89 · 2017: 99 · 2016: 65 · 2015: 19
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- eScholarship@McGill (McGill) (submittedVersion)
- Funders
- Howard Hughes Medical Institute (55007654)
- Canadian Institutes of Health Research (MOP115-195, MOP#115126, 106530_1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Keywords
- mRNA translation, translation machinery, cancer, eIF4F, translation initiation, oncogenes, tumour suppressor, anticancer agents, intra-tumour heterogeneity, drug development
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, RNA, Messenger, Protein Biosynthesis, Gene Expression Regulation, Neoplastic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.